Baker Bros Raises Its KNSA Stake to 7.7%

Steve Strazza
October 9, 2024

The most notable insider activity on today's list comes via a 13D filing by Baker Bros Advisors.

The hedge fund increased its ownership stake in Kiniksa Pharmaceuticals $KNSA from 6.94% to 7.70%.

Baker Bros' top holdings include BeiGene, Incyte, and Acadia Pharmaceuticals. These three positions represent roughly 50% of its portfolio.

We keep a close eye on what Baker Bros is up to -- the firm is better than anyone when it comes to biotech investing. It has a knack for spotting early-stage winners and sticking with them. 

Its increased stake in KNSA means Baker Bros thinks this one will be a winner in the future. 

We agree.

Here’s The Hot Corner, with data from October 8, 2024:

241009_hot_corner_table
Article Sales Message

Know the trading behavior of …

  • Senators
  • House Of Representatives
  • C-Suite Executives
  • Hedge Fund Managers
  • Other Big-Power Players

Our experienced team of analysts work through the Form 4, 13D and 13G filings to provide you a list of the best trade ideas.

You need to have a subscription to access this content in full.

Log in or subscribe
Filed Under: